Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 20th. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -0.38% in last session and finished the day at $6.53. Traded volume was 16.31million shares in the last session and the average volume of the stock remained 3.84million shares. The beta of the stock remained 1.36. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) insider ownership is 1.00%.

Insmed Incorporated (NASDAQ:INSM) announced that the U.S. Food and Drug Administration (the “FDA”) granted ARIKAYCE™, or liposomal amikacin for inhalation, Breakthrough Therapy Designation for the treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory. Insmed Incorporated (NASDAQ:INSM) rose 42.64 percent to $17.78 Wednesday on volume of 12.08million shares. The intra-day range of the stock was $16.05 to $17.96. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $698.27million.

Drug maker Gilead Sciences, Inc. (NASDAQ:GILD), reported Sovaldi sales of $2.3 billion worldwide in just the first three months of this year. Gilead will not disclose its pricing methods, but vice president Gregg Alton said the drug’s high cure rate makes it “a real huge value.”Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on June 18, 2014 reported a decrease of -0.40% to the closing price of $79.47. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $122.04billion. The overall volume in the last trading session was 10.44million shares. In its share capital, GILD has 1.54billion outstanding shares.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 12 announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). On Wednesday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) advanced 2.66% to close the day at $6.55. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -0.76%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is -20.02%.

MannKind Corporation (NASDAQ:MNKD) VP Diane Palumbo sold 17,902 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $10.59, for a total value of $189,582.18. Following the sale, the vice president now directly owns 140,956 shares in the company, valued at approximately $1,492,724. MannKind Corporation (NASDAQ:MNKD) stock performance was -0.57% in last session and finished the day at $10.54. Traded volume was 5.99million shares in the last session and the average volume of the stock remained 12.09million shares. The beta of the stock remained 1.19. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%.